检索结果 - Christoph Klade

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8<sup>+</sup>T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses

    Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8<sup>+</sup>T Cells in HCV-Seronegative Individuals: Implications for Vaccin... 由 Shihong Zhang, Rakesh K. Bakshi, Pothakamuri Venkata Suneetha, Paraskevi Fytili, Dinler A. Antunes, Gustavo Fioravanti Vieira, Reinhilde Jacobs, Christoph Klade, Michael P. Manns, Anke Kraft, Heiner Wedemeyer, Verena Schlaphoff, Markus Cornberg

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

    Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo 由 Emmanuelle Verger, Juliette Soret‐Dulphy, Nabih Maslah, Lydia Roy, Jérôme Rey, Zineb Ghrieb, Róbert Královics, Heinz Gisslinger, Barbara Grohmann-Izay, Christoph Klade, Christine Chomienne, Stéphane Giraudier, Bruno Cassinat, Jean‐Jacques Kiladjian

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

    Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera 由 Heinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer‐Ausch, Josef Thaler, Ernst Schloegl, Guenther Gastl, Dominik Wolf‎, Róbert Královics, Bettina Gisslinger, Karin Strecker, Alexander Egle, Thomas Melchardt, Sonja Burgstaller, Ella Willenbacher, Martin Schalling, Nicole C.C. Them, Pavla Kadlecová, Christoph Klade, Richard Greil

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

    Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment 由 Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian, Heinz Gisslinger, Jean‐Jacques Kiladjian

    出版 2023
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  5. 5
    Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b

    Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b 由 Nicole C.C. Them, Klaudia Bagienski, Tiina Berg, Bettina Gisslinger, Martin Schalling, Doris Chen, Veronika Buxhofer‐Ausch, Josef Thaler, Ernst Schloegl, Guenther Gastl, Dominik Wolf‎, Karin Strecker, Alexander Egle, Thomas Melchardt, Sonja Burgstaller, Ella Willenbacher, Oleh Zagrijtschuk, Christoph Klade, Richard Greil, Heinz Gisslinger, Róbert Královics

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP)

    Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP) 由 Sebastian Rehberg, Sandra Frank, Vladimír Černý, Radek Cihlář, Rainer Borgstedt, Gíanni Biancofiore, Fabio Guarracino, Andreas Schober, Helmut Trimmel, Thomas Pernerstorfer, Christian Siebers, P Dostál, Andrea Morelli, Michael Joannidis, Ingrid Pretsch, Christian Fuchs, Tim Rahmel, Matej Podbregar, Éva Duliczki, Kadri Tamme, Martin Unger, Jan Sus, Christoph Klade, Kurt Krejcy, Nairi Kirchbaumer-Baroian, Günther Krumpl, František Duška

    出版 2024
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

    Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b 由 Jean‐Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Heinz Gisslinger, Jean‐Jacques Kiladjian, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Heinz Gisslinger

    出版 2022
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  8. 8
    ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

    ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 由 Jean‐Jacques Kiladjian, Francisca Ferrer‐Marín, Haifa Kathrin Al‐Ali, Alberto Álvarez‐Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer‐Ausch, O Cerná, Ana-Manuela Crisan, Catalin Doru DANAILA, Valerio De Stefano, Konstanze Döhner, Victoria Empson, Joanna Góra‐Tybor, Martin Grießhammer, Sebastian Grosicki, Paola Guglielmelli, Valentín García‐Gutiérrez, Florian H. Heidel, Árpád Illés, Ciprian Tomuleasa, Chloé James, Steffen Koschmieder, Maria‐Theresa Krauth, Kurt Krejcy, M. Lazaroiu, Jiřı́ Mayer, Zsolt György Nagy, Franck‐Emmanuel Nicolini, Francesca Palandri, Vassiliki Pappa, Andreas Reiter, Tomasz Sacha, Stefanie Schlager, Stefan Schmidt, Evangelos Terpos, Martin Unger, Albert Wölfler, Blanca Xicoy Cirici, Christoph Klade

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: